| SAN DIEGO, CA–(Marketwired – December 01, 2016) – NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the exhibiting of the Company’s recently launched Integrated Global Alignment™ (iGA) for the Cervical Spine at the Cervical Spine Research Society (CSRS) 44th Annual Meeting in Toronto. NuVasive recently expanded its iGA platform to support all spine procedures, including cervical alignment, making NuVasive the first company to offer a solution to address spinal alignment for all spine procedures.
“Our mission is to help surgeons achieve total sagittal alignment and deliver more predictable clinical outcomes for patients through global alignment of the spine,” said Jason Hannon, NuVasive’s president and chief operating officer. “With the newly expanded iGA platform, we expect to build off of the tremendous momentum we have seen with iGA to meet the needs of patients with varying cervical pathologies.” iGA is a proprietary, procedurally-integrated platform of specialized tools and software designed to help surgeons achieve more precise spinal column alignment. The expanded platform provides surgeons an intuitive software workflow to pre-plan their surgical procedure and then confirm achievement of the desired correction both intraoperatively and post-operatively. It also includes hardware tools, such as Bendini® OCT computer assisted rod bending technology, VuePoint® II OCT fixation system, and the CoRoent® Small Interlock Hyperlordotic system, that enhance the surgeon’s ability to achieve the intended spinal alignment. The newly launched CoRoent Small Interlock Hyperlordotic system allows surgeons to address cervical sagittal deformities from an anterior approach with interbodies that have up to 20 degrees of lordosis. NuVasive is committed to a global approach for assessing, preserving and restoring spinal alignment in an effort to promote surgical efficiencies, lasting patient outcomes and improved quality of life. NuVasive’s differentiated technology helps surgeons:
NuVasive CSRS Participation Details NuVasive will showcase and demo its new technologies at NuVasive Booth #417 on the CSRS exhibit floor. In addition, the Company will host a CSRS Symposium where attendees will have the opportunity to understand the clinical rationale for restoring and/or preserving sagittal balance in the cervical spine. Following the presentation, faculty will demonstrate computer-assisted surgery techniques including case examples. Hands-on with the technologies will be available at the conclusion of the workshop. DATE: Thursday, December 1 at 12:00 p.m. — 2:30 p.m. LOCATION: Westin Harbour Castle — Yonge room CSRS TOPIC: Cervical Spinal Deformity and Complex Osteotomies TITLE: Cervical Alignment Matters™: Emerging Techniques to Restore Global Alignment with Computer-assisted Surgery FACULTY: Donald J. Blaskiewicz, M.D., Themistocles Protopsaltis, M.D., and Neill M. Wright, M.D. About NuVasive NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $811 million in revenues (2015), NuVasive has an approximate 2,200 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com. Forward-Looking Statements NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made. Contact InformationInvestor Contact: Media Contact: |
